Teva Pharmaceutical Industries has reported positive Phase 2a results for TEV-408, an investigational anti-interleukin-15 monoclonal antibody being developed as a potential pharmacological treatment for celiac disease. The randomized, placebo-controlled study enrolled 50 adults already following a gluten-free diet and deliberately exposed them to gluten for six weeks after a single subcutaneous dose of TEV-408 or placebo. At week eight, patients receiving TEV-408 experienced significantly less deterioration in the trial’s biopsy-based primary measure of intestinal damage, giving Teva an early human efficacy signal in a disease for which strict dietary avoidance remains the principal standard of care.
The result is particularly interesting because TEV-408 did not merely improve a symptom questionnaire. Teva measured structural injury in the small intestine using the villous height-to-crypt depth ratio, or Vh, a histological measure reflecting the villous flattening and crypt changes characteristic of active celiac disease. The least-squares mean change from baseline was minus 0.43 with TEV-408 compared with minus 0.88 under placebo, producing a treatment difference of 0.45 with a 95% confidence interval of 0.06 to 0.84 and a p-value below 0.05.
How did Teva deliberately test TEV-408 against gluten exposure?
Participants entered the study while adhering to a gluten-free diet and with minimal intestinal injury at baseline, defined in part by a Vh ratio of at least 2.0. Two weeks after receiving one dose of TEV-408 or placebo, patients began a six-week daily gluten challenge designed to provoke the biological process the drug is intended to suppress. Investigators then assessed intestinal biopsies, inflammatory-cell density and patient-reported gastrointestinal symptoms at the end of the challenge.
This design makes the study more informative than simply observing patients in everyday life, where the amount and timing of accidental gluten exposure can be difficult to quantify. By deliberately introducing gluten under controlled conditions, investigators could test whether IL-15 blockade changes the biological response to a known disease trigger. The trade-off is that the 50-patient Phase 2a trial remains small and short, so it cannot yet establish whether TEV-408 provides durable protection during years of ordinary dietary exposure.
What happened to inflammatory cells in patients receiving TEV-408?
Teva reported a particularly large difference in intraepithelial lymphocyte density, another marker associated with celiac intestinal inflammation. Patients receiving placebo showed a least-squares mean increase of 27.60 in IEL density, while TEV-408-treated participants showed an increase of only 0.37, resulting in a treatment difference of minus 27.23. The confidence interval ranged from minus 39.67 to minus 14.79, supporting a clear pharmacodynamic effect on the intestinal immune response during gluten exposure.
Patients receiving TEV-408 also had lower gastrointestinal symptom scores than placebo according to the Celiac Disease Symptom Diary. Teva has not yet released the full numerical symptom dataset, which limits detailed assessment of how strongly the biopsy improvements translated into everyday patient experience. Additional analyses are underway, and the company intends to present a more complete dataset at a future scientific meeting.
Why is Teva targeting interleukin-15 in celiac disease?
Celiac disease is an autoimmune condition in which gluten exposure triggers an immune response capable of damaging the small intestine. Interleukin-15 is implicated in activation and persistence of immune cells involved in that tissue damage, making it an attractive target for a treatment intended to interrupt the disease process rather than simply help patients manage exposure. TEV-408 is a human monoclonal antibody designed to inhibit IL-15 with a prolonged half-life that Teva believes could support relatively infrequent subcutaneous administration.
The company received FDA Fast Track designation for TEV-408 in celiac disease in May 2025, which can facilitate regulatory interaction but does not imply that the treatment has been shown safe or effective enough for approval. Teva is also studying the same antibody in vitiligo, where IL-15 is involved in immune-mediated destruction of pigment-producing melanocytes. The company views the molecule as a potential “pipeline in a product” if one mechanism can generate clinically meaningful results across several immune-mediated diseases.
Could TEV-408 allow people with celiac disease to eat gluten normally?
The current evidence does not support that conclusion. The Phase 2a trial shows that one TEV-408 dose reduced biological damage during a controlled six-week gluten challenge, but it does not demonstrate that patients can abandon a gluten-free diet or consume unrestricted gluten safely over long periods. Any eventual label would depend on substantially larger trials defining the degree of protection, dosing frequency and residual risk during accidental or intentional exposure.
That distinction is important because celiac disease affects approximately 1% of the global population and can produce complications even when symptoms are relatively mild. A medicine capable of protecting against inadvertent contamination could have significant clinical value without needing to become a license for unrestricted gluten consumption. Teva will now need to determine what therapeutic claim is realistic and how that claim should be tested in later-stage trials.
What safety signals appeared in the Phase 2a study?
Teva said TEV-408 was well tolerated and that no emerging safety signals had been identified in the topline analysis. That is encouraging for a treatment that may ultimately require repeated long-term administration, but a 50-person study is too small to characterize uncommon adverse reactions reliably. Larger and longer studies will need to determine whether sustained IL-15 inhibition changes infection risk or creates other immune consequences that are not apparent after limited exposure.
The company has additional safety information from its broader TEV-408 development program, including work in vitiligo, but indication-specific trials remain necessary because dose, patient population and treatment duration can differ. The Phase 2a result therefore clears an important efficacy hurdle without resolving the broader benefit-risk profile required for commercialization.
Why does Royalty Pharma have a stake in TEV-408’s future?
Teva entered a strategic funding agreement with Royalty Pharma in January 2026 under which Teva can receive as much as $500 million to accelerate development of TEV-408. If the medicine ultimately reaches approval and commercial launch, Teva will owe Royalty Pharma a milestone payment and royalties on worldwide net sales. The structure gives Teva additional development capital while allowing Royalty Pharma to participate economically if the asset becomes a commercial success.
The positive celiac result therefore matters beyond one small Phase 2 trial. It provides another clinical validation point for an asset being developed across multiple immune-mediated diseases and helps justify continued investment in a program large enough to require outside financing. The next question is whether Teva can reproduce the protective effect in a substantially larger patient population under conditions that resemble real-world celiac management.
